Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
- PMID: 32460003
- DOI: 10.1016/j.trecan.2020.02.020
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
Abstract
Chemoresistance is a major factor driving tumour relapse and the high rates of cancer-related deaths. Understanding how cancer cells overcome chemotherapy-induced cell death is critical in promoting patient survival. One emerging mechanism of chemoresistance is the tumour cell secretome (TCS), an array of protumorigenic factors released by tumour cells. Chemotherapy exposure can also alter the composition of the TCS, known as therapy-induced TCS, and can promote tumour relapse and the formation of an immunosuppressive tumour microenvironment (TME). Here, we outline how the TCS can protect cancer cells from chemotherapy-induced cell death. We also highlight recent evidence describing how therapy-induced TCS can impact cancer stem cell (CSC) expansion and tumour-associated immune cells to enable tumour regrowth and antitumour immunity.
Keywords: cancer stem cells (CSCs); chemoresistance; immune escape, tumour cell secretome (TCS); tumour microenvironment (TME); tumour relapse.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.Semin Cancer Biol. 2018 Dec;53:265-281. doi: 10.1016/j.semcancer.2018.10.002. Epub 2018 Oct 11. Semin Cancer Biol. 2018. PMID: 30317036 Review.
-
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer.Trends Cancer. 2021 Jul;7(7):624-634. doi: 10.1016/j.trecan.2020.12.014. Epub 2021 Jan 26. Trends Cancer. 2021. PMID: 33509688 Free PMC article. Review.
-
Cancer Stem Cells and Targeting Strategies.Cells. 2019 Aug 18;8(8):926. doi: 10.3390/cells8080926. Cells. 2019. PMID: 31426611 Free PMC article. Review.
-
Gap Junctions and Breast Cancer Dormancy.Trends Cancer. 2020 Apr;6(4):348-357. doi: 10.1016/j.trecan.2020.01.013. Epub 2020 Feb 20. Trends Cancer. 2020. PMID: 32209448 Review.
-
Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.Nat Rev Clin Oncol. 2020 Apr;17(4):204-232. doi: 10.1038/s41571-019-0293-2. Epub 2019 Dec 2. Nat Rev Clin Oncol. 2020. PMID: 31792354 Review.
Cited by
-
Embryonic protein NODAL regulates the breast tumor microenvironment by reprogramming cancer-derived secretomes.Neoplasia. 2021 Apr;23(4):375-390. doi: 10.1016/j.neo.2021.02.004. Epub 2021 Mar 27. Neoplasia. 2021. PMID: 33784590 Free PMC article.
-
ZIP1+ fibroblasts protect lung cancer against chemotherapy via connexin-43 mediated intercellular Zn2+ transfer.Nat Commun. 2022 Oct 7;13(1):5919. doi: 10.1038/s41467-022-33521-4. Nat Commun. 2022. PMID: 36207295 Free PMC article.
-
Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis.Cells. 2022 Apr 28;11(9):1484. doi: 10.3390/cells11091484. Cells. 2022. PMID: 35563790 Free PMC article. Review.
-
Secretome profiling of Artemisia absinthium extract-loaded polymeric nanoparticle-treated MCF-7 and MDA-MB-231 revealed perturbation in microtubule assembly and cell migration.Front Oncol. 2023 Aug 31;13:1209168. doi: 10.3389/fonc.2023.1209168. eCollection 2023. Front Oncol. 2023. PMID: 37719007 Free PMC article.
-
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors.EMBO Rep. 2025 Jan;26(2):521-559. doi: 10.1038/s44319-024-00333-0. Epub 2024 Dec 11. EMBO Rep. 2025. PMID: 39663510 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical